SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION
Rhea-AI Summary
Sera Prognostics (Nasdaq: SERA) announced that board member Jeff Elliott will step down from its Board of Directors effective June 4, 2026, and will not stand for re-election at the upcoming Annual Meeting.
Elliott, who joined in March 2025, cited increasing demands on his time. Sera is in advanced discussions with highly qualified candidates to join the board and expects to announce a new appointment soon as part of its focus on strong corporate governance and leadership continuity.
AI-generated analysis. Not financial advice.
Positive
- Board succession planning with advanced discussions to appoint a new director
- Emphasis on strong corporate governance and leadership continuity during transition
Negative
- Board member Jeff Elliott departing after a relatively short tenure
Key Figures
Market Reality Check
Peers on Argus
SERA was up 0.93% with light volume, while peers were mixed: ICAD up 3.48%, OWLT down 6.9%, PROF down 1.16%, RCEL down 0.23%, RPID down 1.47%, suggesting a stock-specific backdrop rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | +6.1% | Q1 2026 results with strong PRIME trial data and cash runway to 2029. |
| Apr 22 | Earnings call notice | Neutral | -0.2% | Announcement of May 6, 2026 earnings release and investor conference call. |
| Mar 18 | FY 2025 earnings | Positive | -6.3% | Fourth-quarter and full-year 2025 results with major trial data and financing. |
| Mar 04 | Earnings call notice | Neutral | -4.3% | Scheduling of March 18, 2026 call for Q4 and FY 2025 results. |
| Feb 17 | Investor conference | Neutral | -2.3% | Plan to present and meet investors at TD Cowen health care conference. |
Earnings updates have produced mixed reactions, with one positive move and one sizable selloff despite favorable fundamentals and extended cash runway.
Over the last few months, SERA has focused on early-stage commercialization of its PreTRM test while emphasizing strong liquidity. Earnings releases on Mar 18, 2026 and May 6, 2026 highlighted positive PRIME trial data, limited revenue ($81,000 FY 2025; $14,000 Q1 2026) and cash runway into 2028–2029. Conference announcements and an investor conference appearance drew modest or negative price reactions. Today’s board transition occurs against this backdrop of operational progress but still-early adoption.
Market Pulse Summary
This announcement outlines a planned board transition, with Jeff Elliott stepping down effective June 4, 2026 and the company already in advanced discussions with replacement candidates. It comes after recent earnings updates emphasizing PRIME trial data and a cash runway into 2028–2029. Investors may watch how the new director complements SERA’s commercialization focus and governance structure while the stock trades below its $2.73 200-day moving average.
AI-generated analysis. Not financial advice.
Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Company.
"I have greatly valued my time serving on Sera's Board and remain confident in the Company's mission and long-term opportunity," said Mr. Elliott. "While I continue to believe strongly in the future of Sera, I have made the decision to step down due to increasing demands on my time and my desire to ensure the Company receives the level of focus it deserves."
Zhenya Lindgardt, Chief Executive Officer of Sera, added, "On behalf of the entire Board and management team, I want to thank Jeff for his thoughtful counsel, contributions and support during his tenure. His perspective has helped shape our strategy, and we are grateful for the role he has played in our progress."
Separately, as part of its ongoing focus on strong corporate governance and leadership continuity, the Company is in advanced discussions with highly qualified candidates to join the Board and expects to announce an appointment in the near term.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2025 March of Dimes Report Card shows that, for the fourth consecutive year, the United States earned a D+ grade for preterm birth, marking the longest stretch of the lowest grade in Report Card history. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Jeff Elliott stepping down from the Company's Board of Directors; the Company's expectation to announce a new Board appointment in the near future; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Investor Contact
Jennifer Zibuda, Head of Investor Relations
jzibuda@sera.com
+1 (801) 396-8043
Media Contact
Nicole Kaplan at Allison Worldwide
sera@allisonworldwide.com
+1 (847) 721-6033
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-board-transition-302787324.html
SOURCE Sera Prognostics, Inc.